Sarepta Therapeutics Inc (SRPT)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 1,103,010 | 197,855 | 383,622 | 427,290 | 428,430 | 541,932 | 851,929 | 871,668 | 966,777 | 1,038,620 | 868,565 | 1,233,880 | 2,115,870 | 1,599,110 | 1,697,280 | 1,481,840 | 1,502,650 | 1,474,640 | 1,639,960 | 1,764,210 |
| Short-term investments | US$ in thousands | 251,782 | 1,000,530 | 1,076,850 | 963,453 | 1,247,820 | 1,191,610 | 1,008,790 | 1,010,430 | 1,022,600 | 1,033,860 | 1,059,450 | 779,548 | 0 | 0 | 30,000 | 255,997 | 435,923 | 341,467 | 421,349 | 406,940 |
| Total current liabilities | US$ in thousands | 731,684 | 699,489 | 688,490 | 608,709 | 653,659 | 450,743 | 498,654 | 536,884 | 619,604 | 602,916 | 545,566 | 454,962 | 452,733 | 373,443 | 425,022 | 364,736 | 416,026 | 378,388 | 354,896 | 306,429 |
| Cash ratio | 1.85 | 1.71 | 2.12 | 2.28 | 2.56 | 3.85 | 3.73 | 3.51 | 3.21 | 3.44 | 3.53 | 4.43 | 4.67 | 4.28 | 4.06 | 4.76 | 4.66 | 4.80 | 5.81 | 7.09 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,103,010K
+ $251,782K)
÷ $731,684K
= 1.85
The cash ratio is a financial metric that indicates a company's ability to cover its short-term liabilities using its cash and cash equivalents. It is calculated by dividing the total cash and cash equivalents by the total current liabilities.
Analyzing the cash ratio of Sarepta Therapeutics Inc over the reporting period from March 31, 2020, to December 31, 2024, we observe fluctuations in the ratio. The cash ratio started relatively high at 7.09 on March 31, 2020, indicating the company had significant cash reserves compared to its short-term liabilities.
However, over the following quarters, the cash ratio gradually decreased to 1.85 by December 31, 2024. This downward trend suggests a reduction in the company's ability to cover its short-term obligations solely with its available cash and cash equivalents.
A declining cash ratio could indicate potential liquidity challenges or inefficiencies in managing short-term obligations. It may also signal an increased reliance on other sources of funding to meet current liabilities.
It is important for stakeholders to closely monitor the cash ratio along with other financial metrics to assess the overall financial health and liquidity position of Sarepta Therapeutics Inc. By doing so, they can make informed decisions regarding the company's financial stability and future prospects.
Peer comparison
Dec 31, 2024